- Home
- AACG vs IPSC Comparison
AACG vs IPSC Comparison
Compare AACG & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACG
- IPSC
- Stock Information
- Founded
- AACG 1999
- IPSC 2019
- Country
- AACG China
- IPSC United States
- Employees
- AACG N/A
- IPSC N/A
- Industry
- AACG Other Consumer Services
- IPSC Medicinal Chemicals and Botanical Products
- Sector
- AACG Real Estate
- IPSC Health Care
- Exchange
- AACG Nasdaq
- IPSC Nasdaq
- Market Cap
- AACG 51.9M
- IPSC 49.1M
- IPO Year
- AACG N/A
- IPSC 2021
- Fundamental
- Price
- AACG $1.16
- IPSC $0.57
- Analyst Decision
- AACG
- IPSC Strong Buy
- Analyst Count
- AACG 0
- IPSC 5
- Target Price
- AACG N/A
- IPSC $3.33
- AVG Volume (30 Days)
- AACG 53.2K
- IPSC 1.4M
- Earning Date
- AACG 11-10-2025
- IPSC 11-07-2025
- Dividend Yield
- AACG N/A
- IPSC N/A
- EPS Growth
- AACG N/A
- IPSC N/A
- EPS
- AACG N/A
- IPSC N/A
- Revenue
- AACG $39,064,701.00
- IPSC $114,128,000.00
- Revenue This Year
- AACG N/A
- IPSC $1,589.94
- Revenue Next Year
- AACG N/A
- IPSC N/A
- P/E Ratio
- AACG N/A
- IPSC N/A
- Revenue Growth
- AACG 15.19
- IPSC 5491.77
- 52 Week Low
- AACG $0.70
- IPSC $0.34
- 52 Week High
- AACG $2.58
- IPSC $1.83
- Technical
- Relative Strength Index (RSI)
- AACG 35.55
- IPSC 51.88
- Support Level
- AACG $1.15
- IPSC $0.55
- Resistance Level
- AACG $1.30
- IPSC $0.63
- Average True Range (ATR)
- AACG 0.12
- IPSC 0.04
- MACD
- AACG 0.01
- IPSC -0.00
- Stochastic Oscillator
- AACG 12.82
- IPSC 30.00
About AACG ATA Creativity Global
ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments of the company are (i) Overseas art study services (ii) Other educational services and (iii) Other services. Majority of its revenue comes from Overseas art study services.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.